Literature DB >> 12711212

Transcriptional abnormalities in Huntington disease.

Katharine L Sugars1, David C Rubinsztein.   

Abstract

Huntington disease (HD) is caused by a CAG repeat expansion that is translated into an abnormally long polyglutamine (polyQ) tract in the huntingtin protein. The precise mechanisms leading to neurodegeneration in HD have not been fully elucidated, but alterations in gene transcription could well be involved because the activities of several nuclear proteins are compromised by the polyQ mutation. Recent microarray studies also show relevant changes in gene expression profiles in HD models, providing useful information on the potential consequences of disrupted transcriptional pathways in HD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12711212     DOI: 10.1016/S0168-9525(03)00074-X

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  178 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock.

Authors:  Yongqing Li; Hasan B Alam
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

4.  Transcriptional control of amino acid homeostasis is disrupted in Huntington's disease.

Authors:  Juan I Sbodio; Solomon H Snyder; Bindu D Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-19       Impact factor: 11.205

Review 5.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

6.  Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes.

Authors:  Manish K Gupta; James Gulick; Ruijie Liu; Xuejun Wang; Jeffery D Molkentin; Jeffrey Robbins
Journal:  Circ Res       Date:  2014-08-05       Impact factor: 17.367

Review 7.  Mutant huntingtin and mitochondrial dysfunction.

Authors:  Ella Bossy-Wetzel; Alejandra Petrilli; Andrew B Knott
Journal:  Trends Neurosci       Date:  2008-10-24       Impact factor: 13.837

8.  Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.

Authors:  Jiu-Qiang Wang; Qian Chen; Xianhua Wang; Qiao-Chu Wang; Yun Wang; He-Ping Cheng; Caixia Guo; Qinmiao Sun; Quan Chen; Tie-Shan Tang
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

Review 9.  Pharmacology of epigenetics in brain disorders.

Authors:  Pritika Narayan; Mike Dragunow
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

10.  Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies.

Authors:  Jeffrey N Savas; Anthony Makusky; Søren Ottosen; David Baillat; Florian Then; Dimitri Krainc; Ramin Shiekhattar; Sanford P Markey; Naoko Tanese
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.